Catalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for Relacorilant in Hypercortisolism. The expected timing is based on the latest available company guidance and may change.
07/29/26:- Cushing’s NDA resubmitted. PDUFA decision expected December 17, 2026.
Verification
Confirm timing and program details against the company announcement or filing.